Drug Profile
Dianhydrogalactitol - Kintara Therapeutics
Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083Latest Information Update: 29 Nov 2023
Price :
$50
*
At a glance
- Originator DelMar Pharmaceuticals
- Developer DelMar Pharmaceuticals; Global Coalition for Adaptive Research; Guangxi Wuzhou Pharmaceutical; Kintara Therapeutics; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cytostatics; Epoxy compounds; Ethylene glycols; Small molecules
- Mechanism of Action Alkylating agents; BRD4 protein inhibitors; Cell cycle inhibitors; DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Lung cancer
- Suspended Diffuse intrinsic pontine glioma; Glioblastoma; Medulloblastoma; Non-small cell lung cancer; Ovarian cancer